Adage Capital Partners GP L.L.C. Makes New $3.87 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Adage Capital Partners GP L.L.C. acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 500,000 shares of the biotechnology company's stock, valued at approximately $3,865,000. Adage Capital Partners GP L.L.C. owned approximately 1.01% of REGENXBIO at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. GAMMA Investing LLC boosted its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after buying an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of REGENXBIO during the 4th quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new position in REGENXBIO during the 4th quarter worth approximately $79,000. Teacher Retirement System of Texas boosted its position in REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock valued at $97,000 after buying an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new stake in shares of REGENXBIO during the fourth quarter worth $97,000. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded down $0.22 during mid-day trading on Monday, reaching $10.18. 159,594 shares of the company's stock were exchanged, compared to its average volume of 821,998. The firm has a 50-day moving average price of $7.16 and a two-hundred day moving average price of $8.07. The firm has a market capitalization of $510.24 million, a price-to-earnings ratio of -2.02 and a beta of 1.11. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $17.35.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. As a group, sell-side analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Ratings Changes

RGNX has been the topic of a number of research reports. The Goldman Sachs Group reduced their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Raymond James initiated coverage on REGENXBIO in a report on Friday, February 7th. They set an "outperform" rating and a $27.00 price target on the stock. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research note on Tuesday, March 18th. HC Wainwright dropped their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Finally, StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.